

Freedom of Information Request: Our Reference CTMUHB_443_23

You asked:

1. How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in Q3'23 (July, August, September 2023)?

a. With BPA/Hemlibra Inhibitor?

2. Please fill in the BPA/Hemlibra products *utilized* in July, August, and September 2023.

July 1st through September 2023		Q3'23 Volume (IU)/mg		Total Patients	Patients	
					Prophylaxis	On demand
	Example: FEIBA	50,000 IU		1	0	0
Hem A Inhibitor Patients						
Haem A Inhibitor Patients	FEIBA	0		0	0	0
	Cevenfacta	0		0	0	0
	NovoSeven	0		0	0	0
	Hemlibra	0		0	0	0
Hem B Inhibitor Patients						
Haem B Inhibitor Patients	FEIBA	0		0	0	0
	Cevenfacta	0		0	0	0
	NovoSeven	0		0	0	0
	Obizur	0		0	0	0
AHA Patients						
AHA Patients	FEIBA	0		0	0	0
	NovoSeven	0		0	0	0
	Obizur	0		0	0	0
	Cevenfacta	0		0	0	0
	Hemlibra	0		0	0	0
Other Use						
FVII deficient	NovoSeven	0		0	0	0
Glanzmann's	NovoSeven	0		0	0	0
Other	NovoSeven	0		0	0	0
Other	Cevenfacta	0		0	0	0

3. How **many** minor and major surgeries did your BPA patients have in July, August, and September 2023?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven	0	0	0	0
FEIBA	0	0	0	0
Obizur	0	0	0	0

4. How **many** minor and major surgeries did your BPA/Hemlibra inhibitor patients have in July, August, and September 2023?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven	0	0	0	0

FEIBA	0	0	0	0
Obizur	0	0	0	0

5. How many **breakthrough bleeds** did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	Inhibitor patients	Q3'23 volume (IU/mg)
Hemlibra	0	0
NovoSeven	0	0
FEIBA	0	0

6. Were there any changes in the total number of acute bleeds treated with factor in Q3'23 as compared to Q2'23? N/A

7. Was there any change in the number of elective surgeries **using factor** in Q3'23 as compared to Q2'23? N/A

<i>Number of Surgeries</i>	<i>BPA</i>
Increase / Decrease / Stable compared to Q2'23?	
How many surgeries occurred in Q3'23?	

8. Have any BPA patients switched products between July 1st through September 30th 2023? What were the reasons for the switches?

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
<i>Example: Haem B Inh.</i>	<i>1 NovoSeven</i>	<i>On-demand</i>	<i>Cevenfacta</i>	<i>Prophy 1x/week</i>	<i>Severe</i>	<i>Patient requested to try out a new product to improve treatment</i>

9. What is the total number of patients treated with NovoSeven at your center?
None

Our response:

We can confirm that Cwm Taf Morgannwg University Health Board (CTM UHB) does not hold this information.

These patients would be treated in the tertiary centre at the University Hospital of Wales (Cardiff and Vale University Health Board). These patients would not be treated in Cwm Taf Morgannwg UHB unless they came in as an emergency or with a new undiagnosed condition, for which we can confirm there were none in the time period.

Therefore, you may wish to redirect your request directly to:
Cardiff and Vale University Health Board - CAV.FOI.Requests@wales.nhs.uk